Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study.

Lampe FC, Porter K, Kaldor J, Law M, Kinloch-de Loes S, Phillips AN; CASCADE Collaboration.

Antivir Ther. 2007;12(2):189-93.

PMID:
17503661
2.

Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.

Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, de Lazzari E, Dauer B, Youle M, Fontas E, Krentz HB, Phillips AN.

Arch Intern Med. 2006 Mar 13;166(5):521-8.

PMID:
16534038
3.

Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database.

Zhou J, Sirisanthana T, Kiertiburanakul S, Chen YM, Han N, Lim PL, Kumarasamy N, Choi JY, Merati TP, Yunihastuti E, Oka S, Kamarulzaman A, Phanuphak P, Lee CK, Li PC, Pujari S, Saphonn V, Law MG.

BMC Infect Dis. 2010 Dec 23;10:361. doi: 10.1186/1471-2334-10-361.

4.

The effect of antiretroviral treatment of different durations in primary HIV infection.

Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K; CASCADE Collaboration.

AIDS. 2008 Nov 30;22(18):2441-50. doi: 10.1097/QAD.0b013e328319ea4e.

PMID:
19005267
5.

A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S; AIEDRP Network.

J Infect Dis. 2006 Sep 15;194(6):725-33. Epub 2006 Aug 15.

6.

Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.

Wyl Vv, Gianella S, Fischer M, Niederoest B, Kuster H, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Günthard HF; Swiss HIV Cohort Study-SHCS.

PLoS One. 2011;6(11):e27463. doi: 10.1371/journal.pone.0027463. Epub 2011 Nov 15.

7.

Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.

Pai NP, Lawrence J, Reingold AL, Tulsky JP.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD006148. Review.

PMID:
16856117
8.

The effect of opportunistic illness on HIV RNA viral load and CD4+ T cell count among HIV-positive adults taking antiretroviral therapy.

Ekwaru JP, Campbell J, Malamba S, Moore DM, Were W, Mermin J.

J Int AIDS Soc. 2013 Apr 1;16:17355. doi: 10.7448/IAS.16.1.17355.

9.

Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.

Lapadula G, Cozzi-Lepri A, Marchetti G, Antinori A, Chiodera A, Nicastri E, Parruti G, Galli M, Gori A, Monforte Ad; ICONA Foundation Study.

AIDS. 2013 Mar 13;27(5):769-79. doi: 10.1097/QAD.0b013e32835cb747.

PMID:
23719349
10.

HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M; ANRS CO6 PRIMO Study Group.

Antivir Ther. 2012;17(6):1001-9. doi: 10.3851/IMP2273. Epub 2012 Aug 6.

PMID:
22865544
11.

Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.

Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, Porter K.

Arch Intern Med. 2012 Sep 10;172(16):1252-5. doi: 10.1001/archinternmed.2012.2719.

PMID:
22826124
12.

CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.

Wolbers M, Battegay M, Hirschel B, Furrer H, Cavassini M, Hasse B, Vernazza PL, Bernasconi E, Kaufmann G, Bucher HC; Swiss HIV Cohort Study.

Antivir Ther. 2007;12(6):889-97.

PMID:
17926643
13.

Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.

Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, Chêne G, Mussini C, Porter K, Bucher HC; CASCADE Collaboration Members.

PLoS Med. 2010 Feb 23;7(2):e1000239. doi: 10.1371/journal.pmed.1000239.

14.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
15.

Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.

Hocqueloux L, Avettand-Fènoël V, Jacquot S, Prazuck T, Legac E, Mélard A, Niang M, Mille C, Le Moal G, Viard JP, Rouzioux C; AC32 (Coordinated Action on HIV Reservoirs) of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS).

J Antimicrob Chemother. 2013 May;68(5):1169-78. doi: 10.1093/jac/dks533. Epub 2013 Jan 20.

16.

No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.

Grijsen ML, Steingrover R, Wit FW, Jurriaans S, Verbon A, Brinkman K, van der Ende ME, Soetekouw R, de Wolf F, Lange JM, Schuitemaker H, Prins JM; Primo-SHM Study Group.

PLoS Med. 2012;9(3):e1001196. doi: 10.1371/journal.pmed.1001196. Epub 2012 Mar 27.

17.

Frequency of HIV-1 viral load monitoring of patients initially successfully treated with combination antiretroviral therapy.

Romih V, Zidovec Lepej S, Gedike K, Lukas D, Begovac J.

PLoS One. 2010 Nov 24;5(11):e15051. doi: 10.1371/journal.pone.0015051.

18.

Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.

Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, Hogg E, Komarow L.

PLoS One. 2009;4(5):e5575. doi: 10.1371/journal.pone.0005575. Epub 2009 May 18.

19.

No change in viral set point or CD4 cell decline among antiretroviral treatment-naïve, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010.

Helleberg M, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Obel N, Gerstoft J.

HIV Med. 2013 Jul;14(6):362-9. doi: 10.1111/hiv.12016. Epub 2013 Feb 21.

20.

Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.

Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, Lange JM, de Wolf F, Reiss P.

Clin Infect Dis. 2008 Mar 15;46(6):933-40. doi: 10.1086/528861.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk